128 related articles for article (PubMed ID: 9068760)
21. The impact of high-dose narrowband ultraviolet A1 on dermal thickness, collagen and matrix-metalloproteinases in animal model of scleroderma.
Karpec D; Rudys R; Leonaviciene L; Mackiewicz Z; Bradunaite R; Kirdaite G; Venalis A
J Photochem Photobiol B; 2017 Aug; 173():448-455. PubMed ID: 28667931
[TBL] [Abstract][Full Text] [Related]
22. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V.
Jacobe HT; Cayce R; Nguyen J
Br J Dermatol; 2008 Sep; 159(3):691-6. PubMed ID: 18544076
[TBL] [Abstract][Full Text] [Related]
23. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells.
Camacho NR; Sánchez JE; Martin RF; González JR; Sánchez JL
J Am Acad Dermatol; 2001 Nov; 45(5):697-9. PubMed ID: 11606918
[TBL] [Abstract][Full Text] [Related]
24. UVA therapy for scleroderma.
Steger JW; Matthews JH
J Am Acad Dermatol; 1999 May; 40(5 Pt 1):787-8. PubMed ID: 10321617
[No Abstract] [Full Text] [Related]
25. Ultraviolet A1 phototherapy.
Dawe RS
Br J Dermatol; 2003 Apr; 148(4):626-37. PubMed ID: 12752118
[TBL] [Abstract][Full Text] [Related]
26. Disabling pansclerotic morphoea of childhood.
Jamalpur I; Mogili HR; Koratala A
BMJ Case Rep; 2018 Feb; 2018():. PubMed ID: 29455178
[TBL] [Abstract][Full Text] [Related]
27. Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report.
Kerr AC; Ferguson J; Attili SK; Beattie PE; Coleman AJ; Dawe RS; Eberlein B; Goulden V; Ibbotson SH; Menage Hdu P; Moseley H; Novakovic L; Walker SL; Woods JA; Young AR; Sarkany RP
Clin Exp Dermatol; 2012 Apr; 37(3):219-26. PubMed ID: 22277060
[TBL] [Abstract][Full Text] [Related]
28. UVA1 therapy for sclerodermic graft-versus-host disease of the skin.
Ständer H; Schiller M; Schwarz T
J Am Acad Dermatol; 2002 May; 46(5):799-800. PubMed ID: 12004332
[No Abstract] [Full Text] [Related]
29. Low-dose broad-band UVA in morphea using a new method for evaluation.
El-Mofty M; Zaher H; Bosseila M; Yousef R; Saad B
Photodermatol Photoimmunol Photomed; 2000 Apr; 16(2):43-9. PubMed ID: 10823310
[TBL] [Abstract][Full Text] [Related]
30. Effects of UVA1 Phototherapy on Expression of Human Endogenous Retroviral Sequence (HERV)-K10 gag in Morphea: A Preliminary Study.
Kowalczyk MJ; Teresiak-Mikołajczak E; Dańczak-Pazdrowska A; Żaba R; Adamski Z; Osmola-Mańkowska A
Med Sci Monit; 2017 Jan; 23():505-512. PubMed ID: 28130554
[TBL] [Abstract][Full Text] [Related]
31. Phototherapy for scleroderma: biologic rationale, results, and promise.
Fisher GJ; Kang S
Curr Opin Rheumatol; 2002 Nov; 14(6):723-6. PubMed ID: 12410098
[TBL] [Abstract][Full Text] [Related]
32. Cross-sectional evaluation of acute adverse reactions during ultraviolet A1 phototherapy.
Richer V; Lui H
Br J Dermatol; 2017 Jul; 177(1):258-259. PubMed ID: 28117483
[No Abstract] [Full Text] [Related]
33. UV-A1 phototherapy for sclerotic skin diseases: implications for optimizing patient selection and management.
Kreuter A; Gambichler T
Arch Dermatol; 2008 Jul; 144(7):912-6. PubMed ID: 18645143
[No Abstract] [Full Text] [Related]
34. Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients.
Connolly KL; Griffith JL; McEvoy M; Lim HW
Photodermatol Photoimmunol Photomed; 2015 Nov; 31(6):289-95. PubMed ID: 26052743
[TBL] [Abstract][Full Text] [Related]
35. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review.
Kroft EB; Berkhof NJ; van de Kerkhof PC; Gerritsen RM; de Jong EM
J Am Acad Dermatol; 2008 Dec; 59(6):1017-30. PubMed ID: 18835066
[TBL] [Abstract][Full Text] [Related]
36. PUVA therapy in disabling pansclerotic morphoea of children.
Scharffetter-Kochanek K; Goldermann R; Lehmann P; Hölzle E; Goerz G
Br J Dermatol; 1995 May; 132(5):830-1. PubMed ID: 7772497
[No Abstract] [Full Text] [Related]
37. PUVA therapy for disabling pansclerotic morphoea of children.
Todd DJ; Askari A; Ektaish E
Br J Dermatol; 1998 Jan; 138(1):201-2. PubMed ID: 9536257
[No Abstract] [Full Text] [Related]
38. Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis.
Rose RF; Turner D; Goodfield MJ; Goulden V
Photodermatol Photoimmunol Photomed; 2009 Jun; 25(3):153-5. PubMed ID: 19438995
[TBL] [Abstract][Full Text] [Related]
39. Pansclerotic morphea treated with UVA: a case report.
Yildirim M; Baysal V; Aridogan BC; Kesici D; Erturan I
J Dermatol; 2003 Aug; 30(8):625-7. PubMed ID: 12928533
[TBL] [Abstract][Full Text] [Related]
40. Fractional carbon dioxide laser versus low-dose UVA-1 phototherapy for treatment of localized scleroderma: a clinical and immunohistochemical randomized controlled study.
Shalaby SM; Bosseila M; Fawzy MM; Abdel Halim DM; Sayed SS; Allam RS
Lasers Med Sci; 2016 Nov; 31(8):1707-1715. PubMed ID: 27510285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
